CTN-0029: A Pilot Study of Osmotic-Release Methylphenidate in Initiating and Maintaining Abstinence in Smokers with ADHD

Eugene Somoza, M.D.
T. John Winhusen, Ph.D.
Lead Investigators

University of Cincinnati
Addiction Sciences Division

The primary objective of this study was to evaluate whether OROS-MPH (Concerta), relative to placebo, increases the effectiveness of standard smoking treatment (i.e., nicotine patch and individual smoking cessation counseling) in obtaining prolonged abstinence for smokers with ADHD.  The study involved 255 participants, recruited from six sites.

Primary Findings

Prolonged abstinence rates for the OROS-MPH and placebo groups did not differ significantly.  OROS-MPH, relative to placebo, effectively treated ADHD and was safe and generally well tolerated.

Primary Outcomes Article: Winhusen TM, et al. Impact of Attention-Deficit/Hyperactivity Disorder (ADHD) Treatment on Smoking Cessation Intervention in ADHD Smokers: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Clinical Psychiatry 2010;71(12):1680-1688. [get article]

    Node Involvement

    Lead Node(s):

  • Ohio Valley Node
  • New England Consortium

  • All Participating Nodes:

  • New England Consortium
  • New York Node
  • Ohio Valley Node
  • Western States Node